New Approaches for Treatment of Advanced Extranodal NK/T-Cell Lymphoma

Cancer Manag Res. 2022 Jan 28:14:401-407. doi: 10.2147/CMAR.S328846. eCollection 2022.

Abstract

Extranodal NK/T cell lymphoma (ENKL) is a rare subtype of lymphoma that shows a poor clinical outcome. The most common sites are the nasal cavity, nasopharynx, paranasal sinuses, tonsils and larynx. Because of P-glycoprotein expression on ENKL cells, ENKL is resistant to anthracycline-based chemotherapy. L-asparaginase-based chemotherapy with or without radiotherapy shows promising outcomes for advanced ENKL, but has limited efficacy in relapsed/refractory ENKL. immune-checkpoint inhibitors, histone deacetylase inhibitors, and monoclonal antibodies are being investigated. In this review, we summarize the new treatments for ENKL.

Keywords: PD-1; extranodal NK/T cell lymphoma; immunotherapy; pathway.

Publication types

  • Review

Grants and funding

This research was supported financially by National Natural Science Foundation of China (81971172), Zhejiang Natural Science Foundation (LY19H160037, LY18C09004), Medical and Health Science and Technology Project of Zhejiang Province (2017KY228, 2018KY003, 2018KY816), The Key Research and Development Program of Zhejiang Province (WKJ-ZJ-1914), Zhejiang Public Welfare Technology Research Program (LGF18H090009) and Health Commission of Zhejiang Province (2018KY020).